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Abstract
Purpose—Plexiform neurofibromas (pNF) are pathognomonic nerve and soft tissue tumors of 
neurofibromatosis type I (NF1), which are highly resistant to conventional chemotherapy and 
associated with significant morbidity/mortality. Disruption of aberrant SCF/c-Kit signaling 
emanating from the pNF microenvironment induced the first ever objective therapeutic responses 
in a recent phase 2 trial. Sunitinib malate is a potent, highly selective RTK inhibitor with activity 
against c-Kit, PDGFR, and VEGFR, which have also been implicated in the pathogenesis of these 
lesions. Here, we evaluate the efficacy of sunitinib malate in a preclinical Krox20;Nf1flox/− pNF 
murine model.
Experimental Design—Proliferation, β-hexosaminidase release (degranulation), and Erk1/2 
phosphorylation were assessed in sunitinib treated Nf1+/− mast cells and fibroblasts, respectively. 
Krox20;Nf1flox/− mice with established pNF were treated sunitinib or PBS-vehicle control for a 
duration of 12 weeks. pNF metabolic activity was monitored by serial [18F]DG-PET/CT imaging.
Results—Sunitinib suppressed multiple in vitro gain-in-functions of Nf1+/− mast cells and 
fibroblasts and attenuated Erk1/2 phosphorylation. Sunitinib treated Krox20;Nf1flox/− mice 
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exhibited significant reductions in pNF size, tumor number, and FDG uptake compared to control 
mice. Histopathology revealed reduced tumor cellularity and infiltrating mast cells, markedly 
diminished collagen deposition, and increased cellular apoptosis in sunitinib treated pNF.
Conclusions—Collectively, these results demonstrate the efficacy of sunitinib in reducing tumor 
burden in Krox20;Nf1flox/− mice. These preclinical findings demonstrate the utility of inhibiting 
multiple RTKs in pNF and provide insights into the design of future clinical trials.
Keywords
Sunitinib malate; Receptor tyrosine kinase; Neurofibromatosis type 1; Plexiform neurofibroma; 
Therapy; Preclinical mouse model
Introduction
Neurofibromatosis type I (NF1) is an autosomal dominant genetic disorder that affects 
approximately 1 in 3,500 individuals worldwide [1]. A hallmark feature of NF1 is the 
development of plexiform neurofibromas, which arise during early life from cranial and 
large proximal peripheral nerve sheaths. Plexiform neurofibromas have been found to affect 
25-40% of children diagnosed with NF1 [2,3]. Although these tumors are considered benign, 
plexiform neurofibromas can cause severe disfigurement, disability, and even mortality from 
infiltration and compression of vital structures or from malignant transformation to 
malignant peripheral nerve sheath tumors (MPNSTs), which can occur in up to 10% of cases 
[4]. Surgical excision is the current standard of therapy for plexiform neurofibromas, 
however this can be technically challenging due to the vascularity and the infiltrative nature 
of these tumors resulting in a high rate of local recurrence as observed in two large 
institutional studies [5,6]. In many cases, the failure of standard therapeutic modalities have 
left patients, clinicians, and the research community searching for more effective treatment 
options.
The indolent growth characteristics of plexiform neurofibromas render them highly resistant 
to conventional cytotoxic chemotherapies. The potential for inducing malignant 
transformation to MPNSTs is another significant concern limiting the use of traditional 
DNA damaging agents in the treatment of these lesions. Thus, the development of targeted 
molecular therapies with the potential to induce growth arrest and/or regression of these 
slow-growing tumors represents a significant area of clinical morbidity.
NF1 is caused by germline mutations in the NF1 tumor suppressor gene, which encodes the 
protein neurofibromin, a p21ras (Ras) guanine triphosphate (GTP)-activating protein (GAP) 
that regulates Ras activation states by accelerating the hydrolysis of active Ras-GTP to 
inactive Ras-GDP [7-12]. Ras-GTP recruits the serine-threonine kinase Raf-1 to the plasma 
membrane which then activates a series of downstream effectors such as Erk1/2 (p42/p44 
MAPK) [13,14] that drive cell proliferation, differentiation, and survival in response to 
extracellular stimuli. Attempts to directly target Ras itself, however, have proven difficult, 
primarily due to its complex post-translational modification/activation. Given these 
limitations, it is necessary to test experimental therapeutics that inhibit RTKs that activate 
Ras in multiple cell types including Schwann cells in pNFs.
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Sunitinib malate is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) 
inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and 
imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib exhibits several key 
characteristics that make it an exceptional candidate for the treatment of NF1-related 
plexiform neurofibromas. Firstly, its biochemical properties include a reported IC50 for c-
Kit between 1 and 10nM, which is a known RTK critical for pNF progression [15]. 
Secondly, sunitinib also inhibits two additional RTKs that are activated in multiple cell types 
within the pNF microenvironment, including: platelet-derived growth factor receptor 
(PDGFR) and vascular endothelial growth factor receptor (VEGFR) [16,17]. Targeting these 
two RTKs in other human cancers with similar molecular aberrations to pNF has shown 
some efficacy in both animal models and early human clinical trials [18,19]. Data from 
previous studies demonstrates that sunitinib inhibits PDGFR and VEGFR with IC50s in the 
nanomolar range [20]. Finally, the safety profile and pharmacokinetics of sunitinib are 
established in pediatric patients through a phase I clinical trial under the direction of the 
Children’s Oncology Group [21].
In this study, we first demonstrated that sunitinib inhibits gain-in-functions within principle 
cellular constituents of the pNF microenvironment including Nf1+/− mast cells and 
fibroblasts, driven by hyperactive, Ras-dependent SCF and PDGF signaling. Further, we 
provide evidence that sunitinib malate induces growth arrest and regression of pNF in 
Krox20;Nf1flox/− mice validating broad inhibition of multiple RTKs as a potential therapy 
for NF1 patients with pNF.
Materials and Methods
Animals
The genetically engineered Krox20;Nf1flox/− mice have been previously described [22]. 
Animal care and experiments were conducted according to the guidelines established by the 
Indiana University Animal Care and Use Committee (IACUC). Progeny from these crosses 
were genotyped by polymerase chain reaction (PCR) as previously described [22].
In vivo experimental design and mouse data
Cohorts of age and sex-matched Krox20;Nf1flox/− mice were generated for drug treatment 
trials as described above. The metabolic activity of plexiform neurofibromas was assessed 
by fluorodeoxyglucose ([18F] FDG) PET/CT imaging at baseline prior to treatment, 6 
weeks, and 12 weeks of therapy as described in detail below. The experimental cohort 
consisted of 17 animals which were administered sunitinib malate 60 mg/kg/day by oral 
gavage. The placebo control group consisted of 9 mice that were administered the vehicle, 
phosphate buffered saline (PBS) by daily gavage. Treatment was initiated in 12- to 13-
months of age. Daily weights were obtained with doses of drug and saline adjusted 
accordingly. Mice were treated for a duration of 12 weeks.
Dissection of Dorsal Root Ganglia and Measurement of Tumor Size
Immediately postmortem, mice were perfused and fixed in 4% paraformaldehyde. The 
dorsal root ganglia and peripheral nerves were dissected microscopically. Tumor volume 
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was derived by the formula approximating the volume for a spheroid = (0.52 × (width)2 × 
length), as measured by calipers in the largest possible dimension according to our 
previously established methodology [23].
Histological Analysis
Paraffin sections were stained with hematoxylin and eosin (H&E), Masson trichrome, and 
toluidine blue to examine the tumor histomorphology as described previously [22]. 
Apoptosis was quantified histologically using TUNEL staining [24].
PET Imaging Analysis
Serial [18F]DG-PET/CT imaging was employed to identify and profile the metabolic activity 
of plexiform neurofibromas at baseline and in response to treatment. CT images were used 
to place a standardized volume of interest (VOI) template over regions lateral to the spinal 
cord for quantification of FDG uptake. Registered and overlaid CT image data were 
subsequently used to map the course of the spinal cord in relation to specific anatomical 
landmarks identified within the vertebral column from the first lumbar (L1) to first sacral 
(S1) spinal levels. Three circular regions-of-interest (ROIs) were then placed at interpolated 
points corresponding to the spinal cord and bilateral dorsal root ganglia (DGRs). The 
circular ROIs then were combined to create VOIs for the spinal cord and bilateral DRGs. 
FDG images were acquired 45 min following injection of 0.5–1.0 mCi of FDG into the tail 
vein. Animals were anesthetized with isoflurane at 40 min post injection to immobilize prior 
to imaging [23].
Fibroblast and mast cell proliferation
Primary bone marrow derived mast cells and fibroblasts were cultured from Nf1+/− mice as 
previously described [25,26]. [3H]Thymidine incorporation assays were performed to 
evaluate fibroblast and mast cell proliferation [27]. Briefly, cells were plated at a 
concentration of 4 × 103 cells/well in 96-well dishes in 200 mL of DMEM supplemented 
with 1% glutamine and 10% fetal calf serum (FCS), in a 37ºC, 5% CO2 humidified 
incubator. Culture media was then switched to serum-free DMEM, and the cells were then 
cultured for 24–72 hrs. Tritiated thymidine ([3H], PerkinElmer Life and Analytical Sciences, 
Boston, MA, USA) was added to cultures 6 hours prior to harvest on glass fiber filters 
(Packard Instrument Co.) and β-emission was measured.
β-Hexosaminidase Release Assay
Mast cell degranulation was evaluated by the β-hexosaminidase release assay [28]. In brief, 
bone marrow derived mast cells (BMMCs) were sensitized at 1 × 106/mL in the presence or 
absence of sunitinib in complete RPMI 1640 supplemented with 1.5 µg/ml anti-
dinitrophenyl (DNP) IgE (clone SPE-7, Sigma-Aldrich) for 2 hours at 37°C in 5% CO2. 
Cells were then washed once in Tyrode’s buffer (130 mmol/L NaCl, 10 mmol/L HEPES, 1 
mmol/L MgCl2, 5 mmol/L KCl, 1.4 mmol/L CaCl2, 5.6 mmol/L glucose, and 0.05% bovine 
serum albumin, pH 7.4) and resuspended at 2 × 106/mL in Tyrode’s buffer. Cells were then 
stimulated with recombinant murine SCF (10 ng/mL, PeproTech) for 5 minutes at 37°C. 
After the cells were spun down, 30 µL of supernatant was transferred to a 96-well flat-
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bottom plate. Then 30 µL of 1 mmol/L p-nitrophenyl-N-acetyl–D-glucosamide was added to 
each supernatant and mixed before incubation for 1 hour at 37°C. The reaction was 
terminated by the addition of 200 µL of 0.1 M Na2CO3-NaHCO3 buffer, and optical density 
was read on a plate reader at a wavelength of 405 nm.
Western Blot Analysis
Western blot was performed to detect the phosphorylation of Erk1/2 following stimulation 
and sunitinib treatment [25,28].
Statistical Methods
Comparison of the mean tumor volume, differences in cellularity, and number of apoptotic 
cells between sunitinib-treated versus placebo-treated groups was performed using Student’s 
t test or analysis of variance (ANOVA) with appropriate post-hoc correction. P values less 
than 0.05 were considered significant. Statistical analyses were performed with Prism 5.0 
software (GraphPad, La Jolla, CA).
Results
Sunitinib inhibits multiple cellular functions, and biochemical activation of Erk1/2 in Nf1+/− 
fibroblasts and mast cells
We first tested whether sunitinib malate inhibits the proliferation of two key constituents of 
the pNF microenvironment, Nf1 heterozygous mast cells and fibroblasts. Baseline 
[3H]thymidine incorporation in unstimulated murine Nf1+/− fibroblasts was measured, 
followed by stimulation with PDGF (50 ng/mL) for 5 minutes in the presence of varying 
concentrations of sunitinib to generate a dose response curve (Figure 1A). At 100 nM of 
sunitinib, Nf1+/− fibroblast thymidine incorporation was reduced to basal levels, concordant 
with previously published results in NIH-3T3 cells [15]. We also observed similar results 
when we tested the ability of sunitinib to inhibit the proliferation of SCF-stimulated Nf1+/− 
mast cells (Figure 1B). We next examined the effects of sunitinib on Nf1+/− mast cell 
degranulation in response to SCF stimulation and found that sunitinib significantly reduced 
β-hexosaminidase release in a dose dependent fashion (p=0.02) (Figure 1C).
Sunitinib is a potent inhibitor of multiple RTKs including c-kit, VEGF, and PDGF. We tested 
the efficacy of sunitinib in inhibiting the biochemical activation of the Ras-MAPK signaling 
cascade, which drives gain-in-functions of multiple NF1(Nf1) haploinsufficient cell types. 
Nf1+/− fibroblasts were stimulated with PDGF (50 ng/mL) for 5 minutes in the presence or 
absence of sunitinib (100 nM). SCF and PDGF stimulation induced a robust increase in 
Erk1/2 phosphorylation in Nf1+/− mast cells (Figure 1D) and fibroblasts (Figure 1E), 
respectively which was markedly attenuated in sunitinib treated cells despite growth factor 
stimulation.
Reduced plexiform neurofibroma number and residual tumor size in Krox20;Nf1flox/− mice 
treated with sunitinib
Age and sex matched Krox20;Nf1flox/− mice (n=17) were treated with sunitinib malate at a 
dose of 60 mg/kg by daily oral gavage or a placebo control vehicle (n=9) as outlined in study 
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schematic presented in Figure 2A. Mice tolerated treatment well with no apparent adverse 
effects. Both vehicle control and sunitinib treated mice exhibited weight loss during the first 
two weeks of treatment, likely due to physiologic effects of the daily oral gavages. Body 
weight was maintained thereafter within 10% of baseline through the remaining ten weeks 
of therapy, with no significant difference between the experimental and control cohorts. 
After 12 weeks of sunitinib therapy, mice were sacrificed to evaluate the extent of residual 
tumor burden. Dorsal root ganglia at each spinal level were dissected microscopically and 
the identification of all suspected plexiform neurofibromas was confirmed by histological 
analysis. We observed a significant reduction in the mean number of plexiform 
neurofibromas per animal in sunitinib-treated Krox20;Nf1flox/− mice, with the sunitinib 
treatment group averaging 2.92 ± 0.51 tumors per mouse compared with 4.83 ± 0.72 tumors 
in the vehicle control treated cohort (p<0.05) (Figure 2B). Furthermore, mean tumor volume 
was reduced by 56% in the sunitinib treated mice as compared to the vehicle treated cohort 
over the same duration of therapy (p< 0.05) (Figure 2C).
Sunitinib therapy alters the plexiform neurofibroma microenvironment
Infiltrating Nf1+/− mast cells and fibroblasts are abundant within the plexiform neurofibroma 
microenvironment and play a critical role in promoting tumor growth and progression 
[16,17,29]. Therefore, we tested whether sunitinib treatment altered the cellular 
microarchitecture of these tumors in vivo. Following 12 weeks of therapy, histological 
sectioning of dorsal root ganglia (DRG) and peripheral spinal nerves were compared 
between the treatment and placebo groups. H&E stained cross-sections from DRG and 
peripheral spinal nerves of Krox20;Nf1flox/− mice treated with sunitinib demonstrate a 
marked decrease in tumor size, cellularity, and microarchitecture in representative plexiform 
neurofibromas compared to animals treated with the vehicle control (Figure 3A, top panel). 
Notably, Masson’s Trichrome staining for collagen was diffuse and strongly positive 
throughout pNFs from the vehicle control cohort, while nearly absent in the sunitinib treated 
plexiforms (Figure 3A, middle panel). Mast cells, though abundant within the PBS treated 
plexiforms (Figure 3A, bottom panel), were dramatically reduced in number per high-power 
field (HPF) when enumerated in toluidine blue stained slides (Figure 3B, p<0.05). Finally, as 
shown in Figures 3C & D, there was a 4-fold increase in the number of apoptotic cells 
observed in the sunitinib treated group (p<0.01) compared to controls. Collectively, these 
observations provide evidence that sunitinib alters both the tumor size and cellular 
architecture of the tumor microenvironment in mice with pNF
Sunitinib treatment inhibits plexiform neurofibroma metabolic activity
In parallel experiments, small animal PET/CT imaging studies were performed to evaluate 
for changes in FDG uptake, which we have previously established as a biomarker of 
response to experimental therapy with imatinib in the Krox20;Nf1flox/− GEMM [23]. Serial 
FDG-PET/CT imaging studies were performed at baseline prior to the initiation of therapy, 
and prior to euthanasia at the end of the study. All image data sets were transformed to 
standardized uptake value units (SUVs) and all voxel values above a threshold of SUV=1.0 
within a three dimensional volume of interest along the spine were integrated to form an 
FDG biomarker index. As expected, placebo treated mice showed a marked increase in the 
FDG uptake both at baseline and the conclusion of the study. By contrast, sunitinib treated 
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animals demonstrated a significant reduction in SUV uptake within the spinal cord and 
dorsal root ganglia at the end of the study (Figure 4A and B). Specifically, the SUV integral 
was reduced by nearly 70% in mice treated with sunitinib for 12 weeks of sunitinib therapy 
(p=0.03), compared to vehicle control mice which showed stable to mildly increased SUV 
integrals upon completion of the treatment course.
Discussion
Plexiform neurofibromas are complex nerve and soft tissue tumors which are 
pathognomonic of NF1, highly resistant to conventional chemotherapy, and associated with 
significant morbidity and mortality. To date, many promising therapies have failed to 
demonstrate efficacy in clinical trials [30-33], underscoring the importance of developing 
preclinical models which accurately recapitulate the biological complexity and growth 
kinetics of these neoplasms. Krox20;Nf1flox/− mice develop diffuse enlargement of 
peripheral nerve roots along the dorsal spinal column closely reminiscent of human 
plexiform neurofibroma tissue both morphologically and histopathologically, which provides 
a preclinical animal model to test experimental therapeutics [23].
Among the principle constituents of the plexiform neurofibroma microenvironment are 
infiltrating Nf1+/− mast cells and fibroblasts which are abundant within these tumors [29]. 
Mast cells are hematopoietic derived immune effector cells which are recruited to the 
microenvironment by aberrant SCF/c-Kit signaling and release a number of deleterious 
inflammatory mediators and trophic factors which potentiate pNF growth and progression 
[17]. Nf1+/− fibroblasts, stimulated by a number of growth factors including PDGF, deposit 
collagen comprising greater than 50 percent of the tumor dry weight [34]. The role of Nf1+/− 
vascular smooth muscle and endothelial cells to pNF initiation and progression is an 
understudied area of NF1 biology. Vascular smooth cell function is primarily controlled by 
PDGF receptor activation [35] and endothelial cell contribution to tumor neoangiogenesis is 
driven primarily by VEGF stimulation [36]. Previous studies demonstrate that both of these 
signaling axis are altered in both Nf1+/− vascular smooth muscle cells [37] and in 
endothelial cells [38]. Finally, Nf1−/− Schwann cells express many of these RTKs and 
secrete pathological concentrations of their respective ligands [39-43] which in part control 
multiple cell functions within the pNF.
Given the complexity of the tumor microenvironment in pNF, targeting multiple RTKs may 
be necessary in treating pNFs which is an emerging paradigm in tumor biology. Specifically, 
kinome analysis of both human and animals with different tumors suggest that inhibiting a 
single RTK can lead to activation of alternative signaling pathways that continue to drive 
tumorigenesis [44-48]. Furthermore, not all drugs inhibit the same target, such as c-kit, 
equivalently. Collectively, these observations provide rationale for testing a drug that inhibits 
multiple RTKs that are activated in pNF.
In comparison to imatinib mesylate which was used in a phase 2 clinical trial that resulted in 
tumor shrinkage in a subset of patients [49], sunitinib possesses greater biochemical 
inhibition of c-kit activity [15], a broader RTK profile [20] predicted to inhibit vascular 
smooth muscle, endothelium, and fibroblast function as well as established early phase 
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safety data in pediatric patients [21]. Based on this rationale, we formally tested whether 
sunitinib would inhibit or reduce pNF progression in a previously established, genetically 
engineered murine model.
Following 12 weeks of treatment, we observed a significant reduction in plexiform 
neurofibroma tumor burden (number and size) and metabolic activity as compared to vehicle 
treated controls. Historically, pNFs are slow growing tumors, even in our murine model, and 
response at 12 weeks has correlated well with tumor response clinically [23,49]. Upon 
completion of the study, postmortem histological analysis demonstrated a marked decrease 
in infiltrating Nf1+/− mast cells (by more than 50 percent) as well as dramatic reduction in 
fibroblast collagen deposition within the tumor microenvironment following sunitinib 
treatment. Additionally, TUNEL staining revealed an increase in apoptotic cells in sunitinib 
treated plexiform neurofibromas. These observations suggest that the biological effects of 
sunitinib treatment may relate not only to its ability to inhibit the recruitment and deranged 
functioning of Nf1 haploinsufficient mast cells and fibroblasts within the tumor 
microenvironment, but also to trigger programmed cell death within the tumors themselves.
FDG-PET was utilized as a biomarker in these studies. Though FDG-PET is not sufficiently 
sensitive in the human system to detect therapeutic effects of drugs on plexiform 
neurofibromas, we found that attenuation in FDG uptake on PET imaging correlated with 
biological response (tumor shrinkage, decreased proliferative index, etc.) to both imatinib 
[23] and sunitinib treatment in the preclinical pNF murine model. Three dimensional, 
volumetric MRI is the modality currently used in clinical protocols for experimental 
therapeutics. The challenge with volumetric MRI is that it is a static measure of tumor 
response. Though FDG-PET imaging is useful only as a preclinical tool for pNF, the 
development of novel PET tracers that can be utilized as a sensitive biomarker in patients is 
an area of great need moving forward.
The results of this study are further supported by recently published data involving a number 
of other complementary pharmacologic approaches. While not directly comparable due to 
different study designs, sunitinib demonstrated a similar reduction in tumor progression in 
mice as imatinib even though each drug targeted different RTKs. To test whether 
administering drugs which target different RTKs in combination will reduce tumors better 
than a single agent will require further detailed studies. These studies are currently 
underway given the potential therapeutic benefit.
In addition, several additional RTKs inhibitors have also been demonstrated to promote 
tumor regression in other spontaneous and xenograft derived pNF models. Sorafenib is a 
multi-RTK inhibitor with activity against c-Kit, PDGFR, and VEGFR although significantly 
less potent than sunitinib with respect to c-kit inhibition (IC50 68 nM vs 10 nM for 
sunitinib). In the spontaneous Nf1flox/flox;DhhCre pNF murine model, sorafenib resulted in a 
modest reduction in tumor burden after eight weeks of treatment [50]. In contrast to the 
Krox20;Nf1flox/− model, Nf1flox/flox;DhhCre mice exhibit robust biallelic inactivation of Nf1 
in primitive glial precursor cells during early embryogenesis (~E12.5) with a recombination 
efficiency on the order of 30-50% [51]. The early and more widespread Nf1 recombination 
in the DhhCre model results in the development of diffuse, rapidly growing pNFs, thereby 
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circumventing the requirement for an Nf1 haploinsufficient microenvironment in the genesis 
of these tumors which exists physiologically in human NF1 patients. Xenograft tumor 
models in athymic nude mice provide another preclinical context to evaluate the efficacy of 
candidate compounds, although the absence of a competent immune system limits their role 
in evaluating contributions of infiltrating mast cells and other inflammatory components of 
the pNF microenvironment which are known to play pivotal roles in tumor initiation and 
progression [17,23]. Nonetheless, nilotinib, a tyrosine kinase inhibitor with activity towards 
Bcr-abl, DDR, PDGFR, and c-kit receptor kinases, also demonstrated tumor shrinkage in 
such a model [52]. Although the biological responses achieved in these studies are difficult 
to directly compare, evidence of reduced tumor burden in multiple preclinical models 
achieved by targeting a similar spectrum of RTKs provides strong impetus for advancement 
of these pharmacotherapies toward early phase clinical studies.
Aside from RTK inhibition, pharmacologic MEK inhibitors including PD0325901 and 
AZ6244 have also demonstrated promising results in preclinical [53] and early phase clinical 
studies (unpublished data). Taken together, these observations provide impetus for the 
rational design of combinatorial strategies simultaneously interfering with paracrine growth 
signals emanating from the pNF microenvironment while also targeting aberrant 
Raf/MEK/ERK pathway activation in tumorigenic Schwann cells. Advantages of such an 
approach might include opportunities to minimize adverse side effects by lowering the 
respective doses of each agent and the potential to overcome drug resistance mechanisms 
mediated through adaptive reprogramming of the kinome [44-48].
In summary, preclinical testing of sunitinib in the Krox20;Nf1flox/− GEMM demonstrated 
reduction in plexiform neurofibroma number and size, decreased mast cell infiltration, 
diminished fibroblast collagen deposition, and reduced metabolic activity (FDG PET uptake) 
of these tumors. This study provides important experimental insights for the design of 
clinical trials that target multiple RTKs that are active in pNFs and underscores the need to 
understand the contribution of distinct biochemical pathways to tumor progression and 
initiation.
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Figure 1. Sunitinib inhibits proliferation, functional activity, and Erk1/2 phosphorylation in 
Nf1+/− fibroblasts and mast cells
(A) Nf1+/− fibroblasts were stimulated with PDGF (50 ng/mL) for 5 minutes in the presence 
of increasing concentrations of sunitinib. [3H]thymidine incorporation was measured as an 
indicator of fibroblast proliferation. A dose dependent response was observed with maximal 
inhibition of Nf1+/− fibroblast proliferative activity at sunitinib concentration of 100 nM. 
*P<0.05, **P<0.01 denotes statistical comparison between sunitinib treated fibroblasts vs 
those stimulated with PDGF alone. (B) Nf1+/− mast cells were then stimulated with SCF (50 
ng/mL) for 5 minutes in the presence or absence of 100nM sunitinib. Proliferation was 
measured by 3H]thymidine incorporation. **P<0.01 comparing mast cells treated with SCF 
plus sunitinib versus mast cells stimulated with SCF alone. (C) Nf1+/− mast cell 
degranulation stimulated by SCF (50 ng/mL) with or without sunitinib (100 nM) was 
quantified via a β-hexosaminidase release assay. **P<0.01 comparing sunitinib plus SCF 
treated mast cells to SCF stimulated mast cells alone. (D) Cultured Nf1+/− mast cells were 
stimulated with SCF (50ng/mL) for 5 minutes in the presence or absence of sunitinib (100 
nM). Erk1/2 phosphorylation was detected by western blot with β-actin shown as a loading 
control. (E) Nf1+/− fibroblasts were stimulated with PDGF (50 ng/mL) for 5 minutes in the 
presence or absence of sunitinib (100 nM). Erk1/2 phosphorylation was detected by western 
blot with β-actin shown as a loading control.
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Figure 2. Sunitinib therapy reduces plexiform neurofibroma tumor burden Krox20;Nf1flox/−mice
(A) Cohorts of age and sex matched Krox20;Nf1flox/−mice were treated with either sunitinib 
or vehicle control (PBS) as outlined in the schematic. Treatment was initiated at a mean age 
of 12-13 months. Drug was administered by daily oral gavage for a duration of 12 weeks. 
Serial PET/CT scans were performed at baseline, 6 weeks, and 12 weeks of treatment in six 
mice from each cohort. Upon reaching the 12 week time point, mice were euthanized and 
tissues were dissected/harvested for histopathological analysis. (B) Mean number of tumors 
from Krox20;Nf1flox/− mice treated with vehicle versus sunitinib. *P< 0.05 comparing 
vehicle to sunitinib. (C) Mean volume of plexiform neurofibromas from peripheral nerves of 
Krox20;Nf1flox/− mice treated with vehicle versus sunitinib. *P< 0.01 comparing vehicle to 
sunitinib.
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Figure 3. Histopathological characterization of plexiform neurofibromas in sunitinib treated 
Krox20;Nf1flox/− mice
(A) Histopathological analysis of the Krox20;Nf1flox/- mice following 12 weeks treatment 
with either sunitinib or vehicle. Representative H&E (top panel), Masson’s Trichrome 
(middle panel), toluidine blue (bottom panel) stained pNF sections are shown for both 
vehicle and sunitinib treated mice (magnification 200x, 1000x). Sunitinib treated pNFs 
demonstrated reduced cellularity, markedly decreased collagen deposition, and reduced mast 
cell infiltration. Red arrowheads denoted toluidine blue stained mast cells within the pNF 
microenvironment. (B) The number of infiltrating mast cells per high power field (HPF) 
were counted in toluidine blue stained sections of tumors from Krox20;Nf1flox/− mice 
treated with sunitinib compared to the vehicle control (n=8 animals per group). *P<0.001 
comparing sunitinib treated mice to the vehicle control. (C) Representative 
photomicrographs of immunohistochemical TUNEL staining performed on pNFs from 
vehicle vs sunitinib treated Krox20;Nf1flox/− mice (400x magnification). Red arrowheads 
denote apoptotic cells identified by TUNEL staining. (D) The number of TUNEL positive 
cells per HPF in pNFs from the sunitinib treated cohort versus the vehicle control were 
enumerated by manual counting. (n=7 animals per group). *P<0.001 denotes statistical 
comparison between sunitinib and the vehicle control groups.
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Figure 4. FDG-PET/CT imaging of plexiform neurofibroma metabolic activity in sunitinib and 
vehicle treated mice
(A) Tumor metabolic activity was assessed by serial PET/CT imaging of FGD uptake in 
sunitinib and vehicle treated Krox20;Nf1flox/− mice (n = 6 animals per group). The SUV 
integral represents a measure FDG retention within a 3D volume of interest including the 
spinal cord and bilateral spinal nerve roots. Blue bars represent the SUV integral at baseline 
prior to treatment, red bars after 6 weeks of treatment, and green bars at the 12 weeks 
endpoint. The SUV integral (as a percentage of baseline) was significantly reduced in the 
sunitinib treated mice as compared to the vehicle treated cohort after 12 weeks of treatment. 
*P<0.05 denotes statistical comparison between 12 weeks of sunitinib treatment versus 
baseline. (B) FDG-PET imaging in a representative sunitinib treated mouse at baseline and 
12 week time points. The dotted box represents the SUV region of interest for assessing 
FDG uptake over the dorsal root ganglia and spinal column.
Ferguson et al. Page 17
Pediatr Blood Cancer. Author manuscript; available in PMC 2016 May 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
